EP0564587A1 - Procede pour preparer en phase de solution un peptide - Google Patents

Procede pour preparer en phase de solution un peptide

Info

Publication number
EP0564587A1
EP0564587A1 EP92903706A EP92903706A EP0564587A1 EP 0564587 A1 EP0564587 A1 EP 0564587A1 EP 92903706 A EP92903706 A EP 92903706A EP 92903706 A EP92903706 A EP 92903706A EP 0564587 A1 EP0564587 A1 EP 0564587A1
Authority
EP
European Patent Office
Prior art keywords
boc
trp
lys
phe
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92903706A
Other languages
German (de)
English (en)
Other versions
EP0564587A4 (en
Inventor
David Stevenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0564587A1 publication Critical patent/EP0564587A1/fr
Publication of EP0564587A4 publication Critical patent/EP0564587A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/064—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for omega-amino or -guanidino functions

Definitions

  • This invention relates to a process for preparing the peptide:
  • This peptide has pituitary growth hormone releasing activity.
  • This invention also relates to intermediates used in the process of the invention.
  • the method of preparing this peptide which is exemplified in U.S. 4,411,890 is a solid phase process in which the starting material amino acid is attached to a resin and is then coupled stepwise with the appropriate amino acids.
  • the intermediates in the solid phase process are peptide-resin compounds.
  • the desired peptide product is cleaved from the resin by treatment with hydrogen fluoride.
  • This invention provides an advantageous process for preparing L-His-D-Trp-L-Ala-L-Trp-D-Phe-L-Lys-NH2.
  • the process is a solution phase method which provides solid, recrystallizable intermediates which are readily isolated and purified. These solid intermediates are generally crystalline and may be purified by recrystallization. Solid, recrystallizable intermediates, particularly in all steps of a process, are rare in peptide chemistry and offer an advantage in purification.
  • this invention is a process for preparing a compound of the formula:
  • hich comprises : a) coupling L-Lys (BOO -NH2 with Z-D-Phe; b) removing the Z group and coupling the resulting D- Phe-L-Lys(BOC)-NH 2 with Z-L-Trp-NH 2 ; c) removing the Z group and coupling the resulting L- Trp-D-Phe-L-Lys (BOC)-NH 2 with Z-L-Ala; d) removing the Z group and coupling the resulting L- Ala-L-Trp-D-Phe-L-Lys(BOC)-NH 2 with Z-D-Trp; e) removing the Z group and coupling the resulting D- Trp-L-Ala-L-Trp-D-Phe-L-Lys (BOC)-NH 2 with (BOC) 2 -L-His; and f) removing the BOC groups to give L-His-D-Trp-L
  • the intermediates are preferably recrystallized at each step in the process to prevent the build up of impurities.
  • the purifi ⁇ * " -.ion of the final product is facilitated.
  • the solution phase method of this invention avoids the use of corrosive hydrogen fluoride which is used in the solid phase procedure to cleave the product from the resin.
  • the solution phase process of the invention requires only one acid treatment (at the end of the reaction process to remove the amino protecting groups) , thus minimizing decomposition of the tryptophan residues; whereas, the solid phase method involves repetitive acid treatments.
  • Protected peptide intermediates in the process of this invention are also a feature of this invention.
  • the intermediates are particularly useful in the process of this invention because they are solids, generally crystalline and are readily purified by recrystallization.
  • the 'process of this invention may be represented as follows:
  • L-Trp L-tryptophan
  • L-Ala L-alanine
  • WSC water soluble carbodiimide [1- (3-dimethylamino- propyl) -3-ethylcarbodiimide hydrochloride]
  • intermediates (I) -(VI) are recrystallized before being used in the subsequent steps.
  • Intermediates (II) -(VI) are prepared by removing the benzyloxycarbonyl group (Z) by catalytic hydrogenolysis and then coupling with the appropriate amino acid.
  • N( ⁇ ) -benzyloxycarbonyl-N( ⁇ ) -t- butyloxycarbonyl-L-lysine amide (I) is prepared from N( ⁇ )- benzyloxycarbonyl-N( ⁇ )-t-butyloxycarbonyl-L-lysine by reacting with ammonia, water soluble carbodiimide [i.e. I- 3 (dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride], and 1-hydroxybenzotriazole.
  • the t-butyloxycarbonyl groups are removed using acid, optionally and a carbonium ion scavenger.
  • Suitable acids for removing the t-butyloxycarbonyl group are well known in the art, and include mineral acids or strong organic acids, such as trifluoroacetic acid.
  • Carbonium ion scavengers are also well known in the art, and include electrophilic aryl compounds and mercaptans, such as n-propylmercaptan.
  • the hydrogenolysis to remove Z protecting groups is performed using an appropriate catalyst, for example palladium on carbon, such as 5-10% palladium on carbon. Preferably, 10% palladium on carbon is. used.
  • the pressure at which the hydrogenolysis is performed is not critical, and may be performed at from atmospheric pressure up to several hundred psi. Typically, it is performed at atmospheric pressure up to 100 psi. Increasing the hydrogen pressure enhances the rate of reaction. Performing the reaction at about 100 psi is preferred. Vigorous stirring, such as about 600 rpm, in the autoclave is very advantageous to increase the reaction rate.
  • Coupling reactions are well known in the art and may be accomplished by activating the carboxyl group of the intermediate, such as by formation of an acyl halide, activated ester or activated anhydride, or coupling with a coupling reagent such as a carbodiimide, for example dicyclohexylcarbodiimide or water soluble carbodiimide, PPA (1-propanephosphonic acid cyclic anhydride) , DPPA (diphenylphosphoryl azide) or BOP reagent (benzotriazol-1- yloxy-tris (dimethylamino)-phosphonium hexafluorophosphate) . Water soluble carbodiimide is preferred.
  • the coupling reaction solutions are poured into aqueous base, for example, in the preparation of intermediates (II)-(V), the coupling reaction solutions are poured into aqueous potassium carbonate or potassium bicarbonate solution with vigorous stirring.
  • the coupling reaction solution is, preferably, poured into aqueous potassium bicarbonate solution.
  • the aqueous potassium bicarbonate is stirred vigorously.
  • the rate of addition should be about 500 mL- 1 L/minute.
  • the BOC protecting groups are removed with acid, optionally in the presence of a carbonium ion scavenger.
  • Trifluoroacetic acid is a suitable acid for removing the BOC group.
  • Use of a carbonium ion scavenger is preferred.
  • Typical carbonium ion scavengers are anisole, dimethoxy benzene and mercaptans.
  • n-Propyl mercaptan is suitable.
  • reaction mixture was filtered through a DMF-washed bed of Celite®. In turn, the solids were rinsed with DMF (35 mL) and the filtrate and washings were combined.
  • reaction mixture was filtered through a DMF-washed bed of Celite® and then was added slowly and with vigorous stirring into aqueous potassium carbonate solution (5% w/v, 1.6 L) .
  • the solid which precipitated was collected on a Buchner funnel and the filter cake washed with deionized water (about 1.2 L) until the eluant was neutral to pH paper.
  • the solid was dissolved in boiling isopropanol (240 mL) . To the boiling solution, deionized water (approximately 240 mL) was added to cloud point; the resulting solution was cooled at 0- 5°C overnight.
  • reaction mixture was filtered through a DMF-washed bed of Celite®. In turn, the solids were rinsed with DMF (50 mL) and the filtrate and washings were combined.
  • reaction mixture When the WSC had dissolved, the reaction mixture was allowed to stir at ambient temperature for 2.5 hours. At this time, TLC indicated the absence of D-Phe-L-Lys (BOC)-NH 2 .
  • the reaction mixture was filtered through a DMF-washed bed of Celite® and then was added slowly and with vigorous stirring into aqueous potassium carbonate solution (5% w/v, 1.6 L) .
  • the product separated as a solid which was collected at the pump and washed with deionized water (1.2 L) until the washings were no longer basic.
  • the damp cake was dissolved in boiling methanol (500 mL) ; deionized water (150 mL) was added to cloud point. The solution was allowed to cool at 0- 5°C overnight .
  • TLC indicated the absence of starting material; HPLC showed a trace to be remaining.
  • the reaction mixture was filtered through a DMF-washed bed of Celite®. In turn, the solids were -rinsed with DMF (50-mL) and the filtrate and washings were combined.
  • the reaction mixture was filtered through a DMF-washed bed of Celite® and then was added slowly and with vigorous stirring into aqueous potassium carbonate solution (5% w/v, 1.6 L) .
  • the product separated as a solid, which was collected at the pump and washed with deionized water (1.6 L) until the washings were neutral.
  • the damp filter cake was dissolved in boiling methanol (700 mL) ; deionized water (300 mL) was added to cloud point. The resulting solution was cooled overnight at 0-5°C.
  • TLC indicated the absence of starting material; HPLC showed a trace to be remaining.
  • the reaction mixture was filtered through a DMF-washed bed of Celite®. In turn, the solids were rinsed with DMF (50 mL) and the filtrate and washings were combined.
  • reaction mixture was filtered through a DMF-washed bed of Celite®. In turn, the solids were rinsed with DMF (50 mL) and the filtrate and washings were combined.
  • reaction mixture was evaporated to a gum which was dissolved in distilled water (300 mL) and re-evaporated twice. Then, the mixture was dissolved in distilled water (1 L) and the pH was adjusted to approximately 3 by the dropwise addition of dilute aqueous ammonium hydroxide solution.
  • This material was purified by reverse phase liquid chromatography using YMC-type AS-5055, end-capped octadecyl silica, spherical in shape, with a particle size of 50 ⁇ and a pore size of 120 A 0 .
  • the bed size was 5 cm i.d. x 50 cm length, corresponding to a bed volume of 981 mL, packed in a stainless steel HPLC column. There was also a guard column of 5 cm i.d. x 10 cm length containing the same packing material (196 mL) .
  • This was equilibrated with 0.1 M aqueous ammonium acetate solution pH 4.5 (4 L) , utilizing a Beckman Prep-350 HPLC system, monitoring the eluant at 254 nm.
  • the above pH adjusted reaction mixture was further diluted with distilled water (300 mL) and then applied to the column at a flow rate of 100 mL/min.
  • the column was washed with 1.0 M ammonium acetate pH 8 (6.0 L), followed by 0.1 M ammonium acetate pH 4.5 (2.5 L) .
  • the product was removed by step-wise elution with solutions of acetonitrile in 0.1 M aqueous ammonium acetate pH 4.5 as follows: 10% v/v (1 L) , 15% v/v (900 mL) , 17% v/v (1 L) , 20% v/v (2.5 L) , 25% v/v (2.5 L) .
  • Fractions were collected, varying in size from 125 mL to 1 L.
  • the column was washed with 50% v/v acetonitrile in 0.1 M aqueous ammonium acetate pH 4.5 (3.5 L) .
  • A 1/4 v/v acetonitrile/water-0.1M ammonium dihydrogen phosphate- 0.8M phosphoric acid (adjusted to pH 3.0 with triethylamine)
  • B 3/7 v/v acetonitrile/water-0.1M ammonium dihydrogen phosphate-0.8M phosphoric acid (adjusted to pH 3.0 with triethylamine), 0% B for 23 min, 0%-100% B over 37 min, UV detection at 210 nm) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procédé pour préparer, en phase de solution, le peptide L-His-D-Trp-L-Ala-L-Trp-D-Phe-L-Lys-NH2, qui fait preuve d'une activité libératrice de l'hormone de croissance hypophysaire.
EP9292903706A 1990-11-30 1991-11-25 Solution phase process for synthesis of peptide Withdrawn EP0564587A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62109490A 1990-11-30 1990-11-30
US621094 1990-11-30

Publications (2)

Publication Number Publication Date
EP0564587A1 true EP0564587A1 (fr) 1993-10-13
EP0564587A4 EP0564587A4 (en) 1994-08-24

Family

ID=24488689

Family Applications (1)

Application Number Title Priority Date Filing Date
EP9292903706A Withdrawn EP0564587A4 (en) 1990-11-30 1991-11-25 Solution phase process for synthesis of peptide

Country Status (10)

Country Link
EP (1) EP0564587A4 (fr)
JP (1) JPH06503578A (fr)
KR (1) KR930703345A (fr)
AU (1) AU9166491A (fr)
CA (1) CA2097305A1 (fr)
IE (1) IE914157A1 (fr)
MX (1) MX9102333A (fr)
PT (1) PT99654A (fr)
WO (1) WO1992009620A1 (fr)
ZA (1) ZA919440B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3480848B2 (ja) * 1992-06-19 2003-12-22 タカラバイオ株式会社 環状ペプチドの合成方法
GB0814519D0 (en) * 2008-08-08 2008-09-17 Imp Innovations Ltd Process

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4105652A (en) * 1977-08-05 1978-08-08 Hoffmann-La Roche Inc. Synthesis of human β-endorphin
US4237046A (en) * 1979-04-27 1980-12-02 Miklos Bodanszky Polypeptides and methods of preparation
WO1992001709A1 (fr) * 1990-07-24 1992-02-06 Eastman Kodak Company Procede de synthese de peptides

Also Published As

Publication number Publication date
AU9166491A (en) 1992-06-25
JPH06503578A (ja) 1994-04-21
ZA919440B (en) 1992-12-30
CA2097305A1 (fr) 1992-05-31
EP0564587A4 (en) 1994-08-24
MX9102333A (es) 1993-06-01
KR930703345A (ko) 1993-11-29
PT99654A (pt) 1992-10-30
IE914157A1 (en) 1992-06-03
WO1992009620A1 (fr) 1992-06-11

Similar Documents

Publication Publication Date Title
RU2515555C2 (ru) Способ получения дегареликса
US6235876B1 (en) Liquid phase process for the preparation of GNRH peptides
EP1212350A1 (fr) Procede de preparation de h-tyr-d-ala-phe(f)-phe-nh 2?
CN109096388A (zh) 一种特立帕肽的制备方法
Li et al. The Synthesis of L-Histidyl-L-phenylalanyl-L-ornithyl-L-tryptophyl-glycine and L-Histidyl-D-phenylalanyl-L-ornithyl-L-tryptophyl-glycine and their Melanocyte-stimulating Activity
JPH04288070A (ja) ペプチド合成使用のためのキサンテニルアミドハンドル
US5712367A (en) Process for the solubilization of peptides and process for peptide synthesis
Müller et al. Synthesis of N‐carboxyalkyl and N‐aminoalkyl functionalized dipeptide building units for the assembly of backbone cyclic peptides
CN117003791B (zh) 一种二苯基膦酰氧基双酚a类化合物及其制备美白九肽-1中的应用
CA2534224C (fr) Preparation de peptides somatostatine
EP0564587A1 (fr) Procede pour preparer en phase de solution un peptide
KR100591832B1 (ko) 트립토판 잔기를 갖는 펩티드의 합성공정
HU208838B (en) Method for producing peptones containing aza aminoacides by means of solid-phase synthesis
Van Nispen et al. INVESTIGATION OF THE ROLE OF TRYPTOPHAN IN α‐MSH*: Replacement by L‐Pentamethylphenylalanine and L‐Phenylalanine
IL105036A (en) Method and intermediates for peptide synthesis containing one or more carbamoyl groups
AU596898B2 (en) Guanidine-related compounds comprising a tetraphenylborate ion, process for obtaining these compounds and use of the compounds in peptide synthesis
EP0410182A2 (fr) Technique pour le couplage rapide des peptides
GB2166139A (en) Biologically active penta- and heptapeptides
JP2927978B2 (ja) Ｌｈ−ｒｈ類似体の一時的最小保護合成法
WO1998046629A1 (fr) Appareil permettant de mettre graduellement fin a une dependance
CN114057829A (zh) 一种n-甲基化多肽的固相合成方法
EP0106282A2 (fr) Préparation d'un intermédiaire de la caéruléine
JPH07316193A (ja) ペプチド誘導体およびその用途
Van Nispen et al. SYNTHESIS AND BIOLOGICAL ACTIVITIES OF TWO ACTH‐ANALOGUES CONTAINING L‐NORARGININE IN POSITION 8
RU2111972C1 (ru) СПОСОБ ПОЛУЧЕНИЯ ПЕПТИДА δ СНА

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19940705

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19960418

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960829